Jing Li, PhD

Dr Li joined EBI in September 2018 from Merck Research Laboratories. Spanning 15 years at Merck with various roles with increased responsibilities, Jing gained in-depth knowledge of drug discovery from target identification, validation to first-in-man cross multiple therapeutic areas. In recent years at Merck as Director of Pharmacology, Jing oversaw small molecule and peptide hit-finding efforts and championed several key initiatives, such as phenotypic screening.

Prior joining Merck, Jing worked in Tularik, Inc for 5 years leading its cancer genomics group after a postdoctoral appointment with Dr. Ramon Parsons at Columbia University where he discovered PTEN tumor suppressor gene.

Over his career, Jing has co-authored more than 50 scientific and patent applications, including the publications in the journals of Science, Nature Genetics.

Jing received his Ph.D. in Microbiology and Immunology from Medical College of Pennsylvania, M.B. in medicine from Shanghai Medical University in China and B.S. in Biochemistry from University of Nevada.